MARKET

TLSA

TLSA

Tiziana Life Sciences Ltd Com
NASDAQ
1.350
-0.020
-1.46%
Pre Market: 1.390 +0.04 +2.94% 04:00 05/19 EDT
OPEN
1.370
PREV CLOSE
1.370
HIGH
1.400
LOW
1.300
VOLUME
40
TURNOVER
0
52 WEEK HIGH
2.600
52 WEEK LOW
1.140
MARKET CAP
171.80M
P/E (TTM)
-11.8838
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at TLSA last week (0511-0515)?
Weekly Report · 1d ago
Tiziana Phase 2 trial for foralumab shows reduced brain inflammation
TipRanks · 4d ago
Tiziana Life Sciences Posts Early PET Data Showing Reduced Brain Inflammation in MSA Trial of Intranasal Foralumab
TipRanks · 4d ago
Tiziana Life Sciences Announces Initial Quantitative PET Imaging Results From The First Two Patients With Multiple System Atrophy In Its Phase 2 Clinical Trial Of Forlumab
Benzinga · 4d ago
Weekly Report: what happened at TLSA last week (0504-0508)?
Weekly Report · 05/11 09:39
Weekly Report: what happened at TLSA last week (0427-0501)?
Weekly Report · 05/04 09:39
Tiziana FY25 net loss widens to USD 18.4 million; R&D expense rises to USD 10.28 million
PUBT · 05/01 21:02
Tiziana Life Sciences Delays Annual 20-F Filing
TipRanks · 04/30 23:34
More
About TLSA
Tiziana Life Sciences Ltd. is a biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Its clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer’s, and Amyotrophic lateral sclerosis. Its lead immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer’s and other CNS indications. Its Anti-IL-6R mAb (TZLS-501), a fully human mAb, binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune and cancer, reducing circulating levels of the IL-6 cytokine. Milciclib is a potent, small molecule inhibitor of multiple cyclin-dependent kinases (CDKs), tropomycinreceptor kinases and Src family kinases controlling cell growth and malignant progression of cancer.

Webull offers Tiziana Life Sciences Ltd - ADR stock information, including NASDAQ: TLSA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TLSA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TLSA stock methods without spending real money on the virtual paper trading platform.